Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Advance Cancer Immunotherapy Techniques and the Future Perspective of Modified T Cell Therapy

Version 1 : Received: 6 May 2021 / Approved: 7 May 2021 / Online: 7 May 2021 (11:10:13 CEST)

How to cite: Al Saber, M.; Biswas, P.; Dey, D.; Kaium, M.A.; Islam, M.A.; Tripty, M.I.A.; Rahman, M.H.; Rahaman, T.I.; Biswas, M.Y.; Paul, P.; Rahman, M.A.; Hasan, M.N.; Kim, B. The Advance Cancer Immunotherapy Techniques and the Future Perspective of Modified T Cell Therapy. Preprints 2021, 2021050142 (doi: 10.20944/preprints202105.0142.v1). Al Saber, M.; Biswas, P.; Dey, D.; Kaium, M.A.; Islam, M.A.; Tripty, M.I.A.; Rahman, M.H.; Rahaman, T.I.; Biswas, M.Y.; Paul, P.; Rahman, M.A.; Hasan, M.N.; Kim, B. The Advance Cancer Immunotherapy Techniques and the Future Perspective of Modified T Cell Therapy. Preprints 2021, 2021050142 (doi: 10.20944/preprints202105.0142.v1).

Abstract

The mechanisms involved in immune responses to cancer have been extensively studied for several decades and, considerable attention has been paid to harnessing the immune system's therapeutic potential. Cancer immunotherapy has established itself as a promising new treatment option for a variety of cancer types. Various strategies including cancer vaccines, monoclonal antibodies (mAbs), adoptive T-cell-cancer therapy and immune test therapy have gained prominence through immunotherapy. However, it remains to be accomplished the full potential of cancer immunotherapy. In spite of having startling aspects, the cancer immunotherapies have some difficulties including the inability to effectively targeting the cancer antigens and the abnormalities in patient response. With the advancement of technology, this system has changed the genome-based immunotherapy process in the human body including generation of engineered T cells. Due to its high specificity, CRISPR-Cas9 has become a simple and flexible genome-editing tool to target nearly any genomic locus. Recently, the CD19-mediated CAR-T cell (chimeric antigen receptor T cell) therapy has opened a new avenue for the treatment of human cancer, though low efficiency is a major drawback of this process. Thus, increasing the efficiency of the CAR-T cell (engineered T cells that induce the chimeric antigen receptor) by using CRISPR-Cas9 technology could be a better weapon to fight against the cancer. In this review, we have broadly focused on the use of CRISPR-Cas9 technology for the modification of the T-cell, which can specifically recognize cancer cells and be used as immune therapeutics against cancer. We have also demonstrated the other potential strategies for the treatment of cancer.

Keywords

Cancer Immunotherapy; Cancer Vaccine; Cancer Antigens; CRISPR-Cas9; Engineered T Cells.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.